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Abstract
Objective: Dendritic cells bind an array of antigens and DC-SIGN has been postulated to act as a receptor for mucosal
pathogen transmission. Bile salt-stimulated lipase (BSSL) from human milk potently binds DC-SIGN and blocks DC-SIGN
mediated trans-infection of CD4
+ T-lymphocytes with HIV-1. Objective was to study variation in DC-SIGN binding properties
and the relation between DC-SIGN binding capacity of milk and BSSL gene polymorphisms.
Study Design: ELISA and PCR were used to study DC-SIGN binding properties and BSSL exon 11 size variation for human
milk derived from 269 different mothers distributed over 4 geographical regions.
Results: DC-SIGN binding properties were highly variable for milks derived from different mothers and between samplings
from different geographical regions. Differences in DC-SIGN binding were correlated with a genetic polymorphism in BSSL
which is related to the number of 11 amino acid repeats at the C-terminus of the protein.
Conclusion: The observed variation in DC-SIGN binding properties among milk samples may have implications for the risk
of mucosal transmission of pathogens during breastfeeding.
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Introduction
Human milk contains a large array of foreign antigens and host
factors that interact with esophageal and gut mucosa of the
breastfed infant [1,2]. There is accumulating evidence that breast
milk protects the newborn against infections as indicated by the
decreased morbidity and mortality due to diarrhea among
breastfed as compared to formula-fed infants [1,3]. Furthermore,
only 4–12% of human immunodeficiency virus type-1 (HIV-1)
positive mothers transmit HIV-1 to their infant during breastfeed-
ing in spite of frequent exposure of the infant to HIV-1 positive
breast milk for up to several years [4]. If we would have a better
understanding of how human milk influences mucosal infections,
we would be able to develop therapeutics aimed at prevention.
The anti-microbial activity of human milk is, at least in part, the
result of secretory antibodies and prebiotic factors. Glycans in
breast milk have been associated with protection against
transmission of specific mucosal pathogens [1,5]. Furthermore,
blood group antigen genes involved in post translational protein
modification and resulting in differentiated glycan fingerprints
have been linked to pathogen driven selection in humans [6]. This
stresses the relevance of glycans in the continuous competition
with rapidly evolving pathogens where one glycan type may
protect against certain pathogens whilst enhance infection with
other pathogens. Although innate immune molecules present in
breast milk can contribute to protection against infection,
additional immune responses need to be activated in the infant
for further effector and memory purposes. Antigen presenting cells
such as dendritic cells (DCs) that capture invading pathogens
through pathogen coat sugars regulate such processes.
Pathogen receptor DC-Specific Intercellular adhesion molecule-
3 Grabbing Non-integrin (DC-SIGN), also known as CD209, is
highly expressed in mucosal tissues and binds a wide range of
pathogens such as HIV-1, Helicobacter pylori and Candida albicans
[7–10]. Such interaction between pathogen and DC-SIGN
expressing cells could occur at damaged epithelia. Normally,
invading pathogens captured by DC-SIGN expressing DCs are
degraded and the processed antigens are subsequently presented to
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invading pathogens is essential for inducing adaptive immune
responses, some pathogens escape from full degradation and in
fact hijack this system to enhance infection [7,11]. The biological
relevance of DC-SIGN in transmission of HIV-1 and Mycobacterium
tuberculosis is supported by linkages between DC-SIGN polymor-
phisms and risk of infection [12,13]. We previously reported that
bile salt-stimulated lipase (BSSL) from human milk strongly binds
to DC-SIGN and interferes with DC-SIGN mediated HIV-1
transmission in vitro [14,15]. Interestingly, BSSL has also been
associated with protection against Norwalk virus infection, which
is a major cause of gastroenteritis [5,16]. These studies indicated
two possible anti-microbial mechanisms for BSSL, either through
binding to DC-SIGN (HIV-1) [15] or binding to the virus particle
(Norwalk virus)[5].
BSSL is a lipase that is present in human blood and breast milk
which aids breastfed infants with the digestion of milk triglycerides
[17,18]. Tissue specific BSSL expression in mice is influenced by
nuclear factor 1-C2 (NF1-C2) and up-regulation of the BSSL gene
is correlated with an increase in the number of differentiated
epithelial cells [19,20]. The human BSSL glycoprotein contains a
mucin-like repeated 11 amino acid motif at the C-terminal tail that
is abundantly modified by O-linked glycosylation. The repeated
motif, encoded by exon 11 of the gene does not play a role in the
enzymatic activity of the lipase [21,22]. Furthermore, the O-
glycosylated repeated motif expresses Lewis a and Lewis x sugars
known to interact with DC-SIGN [23,24]. We previously
described that BSSL binds to DC-SIGN via Lewis x sugars.
Furthermore we suggested that variation in BSSL protein size
among mothers may relate to variation in DC-SIGN blocking
capacities [15].
The aim of this study was to characterize the DC-SIGN binding
properties of breast milk derived from healthy breastfeeding
mothers. Furthermore, we compared BSSL size variations with
DC-SIGN binding capacity of breast milks. Our results reveal that
the DC-SIGN binding capacity of breast milk is highly variable
among mothers as well as among groups of mothers from differing
geographical regions. We were able to correlate allelic polymor-
phisms in the BSSL gene with the DC-SIGN binding phenotype of
breast milk. The observed variation in DC-SIGN binding
properties of different milks may have implications for the risk of
mucosal pathogen transmission during breastfeeding.
Results
BSSL protein size is linked to DC-SIGN binding capacity of
the corresponding human milk
We have previously identified BSSL from human milk as a
strong DC-SIGN binding glycoprotein with variably sized BSSL
isoforms differing in their capacity to bind DC-SIGN [15]. We
hypothesized that the DC-SIGN binding capacity of BSSL and
human milk is correlated with the BSSL protein size. To test this
hypothesis, we determined the BSSL protein size and DC-SIGN
binding capacity of human milk for 17 mothers from the
Netherlands. BSSL protein size was estimated for breast milk
separated by SDS-PAGE (figure 1a). The DC-SIGN binding
capacity of milk was detected by Western blot (figure 1b) and
quantified for all milk samples by ELISA (figure 1c). DC-SIGN
binding capacity was highly variable (figure 1b+c) whereas BSSL
expression levels were similar in the milks for which BSSL protein
size was determined. Although, some milks (not included in this
analysis) had decreased BSSL expression levels these cases did not
correlate to decreased DC-SIGN binding properties of the
corresponding milks. Figures 1a and b represent an example of
milks from different mothers with similar BSSL expression levels
but variable DC-SIGN binding capacities.
We calculated the relative DC-SIGN binding capacity with the
strongest DC-SIGN binding milk arbitrarily set to 100%. We
observed a cluster of 4 samples with weak DC-SIGN binding
properties deviating from the other stronger DC-SIGN binding
milk samples. We then compared BSSL protein sizes of these weak
DC-SIGN binding milks (#20% binding) to strong DC-SIGN
binding milks ($34% binding). Figure 1c shows that the BSSL
protein size was significantly smaller (p=0.020) in the strong DC-
SIGN binding group than in the weak DC-SIGN binding group.
However, linear regression analysis of protein size versus DC-
SIGN binding capacity did not show a significant deviation.
DC-SIGN binding capacity of human milk is highly variant
within and between different cohorts
After identifying variation in DC-SIGN binding capacity of
breast milk derived from a group of mothers from the Netherlands,
we investigated the level of variation within and between different
cohorts. We therefore tested DC-SIGN binding of human milk
derived from the Netherlands (n=78), Sweden (n=21), Norway
(n=146) and Egypt (n=24) using ELISA. Figure 2 shows the DC-
SIGN binding of all breast milk samples with the milk having the
strongest DC-SIGN binding set to 100%. These results show that
DC-SIGN affinity of human milk is highly variable among
mothers in all four cohorts. In addition, significant differences
were apparent between the cohorts. The breast milk samples from
Sweden bound significantly stronger to DC-SIGN than the milks
from the other cohorts (figure 2). Breast milk samples from the
Netherlands had a marginally stronger (p=0.061) DC-SIGN
binding than the tested samples in the Norwegian cohort.
The size of BSSL exon 11 is highly polymorphic
BSSL protein size variation may be related to variation in the
variable number of tandem repeats (VNTR) domain encoded by
BSSL exon 11. BSSL binds to DC-SIGN through Lewis type
sugars present in this VNTR domain that is located at the C-
terminus of the protein [15,23]. We established a PCR to
determine the size of the VNTR domain (figure 3a) and
subsequently estimated the possible number of repeats in each
allele. The VNTR domain is highly variable in the number of
repeats in the populations we tested, with repeat numbers ranging
from 9 to 19 and alleles with 16 repeats being most common
Figure 1. DC-SIGN binding is highly variable and correlates
with BSSL protein size. (a) Example of a coomassie stained SDS-PAGE
separation of breast milk from 7 mothers showing the bile salt-
stimulated lipase (BSSL) of variable sizes. (b) Western blot stained with
DC-SIGN-Fc of the same 7 milks as depicted in figure a. (c) Breast milks
with smaller BSSL protein have stronger DC-SIGN binding capacity than
breast milks with larger BSSL protein. Molecular weights (MW) of BSSL
protein was compared in milks with strong DC-SIGN binding capacity
versus milks with weak DC-SIGN binding capacity. Median protein sizes
in the weak and in the strong DC-SIGN binding groups are indicated by
a horizontal line.
doi:10.1371/journal.pone.0017316.g001
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cohort differs significantly from the European cohorts (p,0.001).
Additionally, the allele frequency distribution in the Norwegian
mothers differs significantly from that in Dutch mothers (p,0.001)
and marginally (p=0.074) from the Swedish mothers. When
looking at the genotype distribution in figure 3c we observed that
79% of all mothers (82% in European cohorts) had at least 1 allele
with 16 repeats.
DC-SIGN binding capacity correlates to BSSL genotype
Differences in BSSL protein size were linked to the DC-SIGN
binding properties of milk (figure 1c). In addition, we hypothesized
that variation in DC-SIGN binding may be caused by size
differences in the VNTR domain of the BSSL gene. To test this
possibility we compared VNTR domain sizes with DC-SIGN
binding potency of the corresponding milks. The majority of tested
mothers have at least one allele with 16 repeats whereas the non-
16 repeat BSSL variants mostly have less than 16 repeats (see
figure 3b). We arbitrarily defined less than 16 repeats as low (L)
and 16 or more repeats as high (H) repeat number. Mothers have
either two low (LL), one allele with low and one with high (LH) or
two alleles with high repeat numbers (HH). The BSSL repeat
number has a significant (p=0.018) effect on the DC-SIGN
binding capacity for all 4 tested cohorts (figure 4a). In the 3
European cohorts we found that mothers with the LH genotype
had significantly stronger DC-SIGN binding milk (p=0.016) than
mothers with the HH genotype. These LH mothers also had
marginally significant stronger DC-SIGN binding milk (p=0.064)
than mothers with the LL genotype. The LL genotype reaches low
frequencies, as the majority of individuals carry at least 1 allele
with high repeat numbers (figure 3c). The H-repeat group
(n=353) mainly exists of 16 repeat BSSL alleles (n=303) and
only 50 alleles having more than 16 repeats. Alleles with more
than 16 repeats are mainly found in the Norwegian population
(n=41).
Discussion
In this study we demonstrate that the DC-SIGN binding
capacity of human milk from different mothers is highly variable.
We confirmed this finding in 4 independent cohorts and report
that variation exists between the samplings from different
geographical regions in the DC-SIGN binding capacity. BSSL
genes have either a high number of repeats (H=16 to 19) or a low
number of repeats (L=9 to 15) in the VNTR domain. We
observed that the combination of an L allele with an H allele (LH)
correlates with strong DC-SIGN binding of breast milk. In
addition, for mothers with at least one BSSL allele of 16 repeats we
report that strong DC-SIGN binding is correlated with a small
repeat number (16+L) in the second allele.
The observed variation in DC-SIGN binding capacity may in
theory be related to diverse factors such as the BSSL expression
level or polymorphisms in the BSSL gene. Analysis of DC-SIGN
binding variation in breast milk samples with similar BSSL protein
levels demonstrates that factors other than BSSL protein
concentration determine the DC-SIGN binding efficiency.
Although we showed that BSSL polymorphisms are correlated
with DC-SIGN binding we do not exclude that in case of breast
milk samples with significantly deviating BSSL protein levels DC-
SIGN binding can be influenced. We previously reported that
BSSL is the major DC-SIGN binding component in human milk,
but mucin 1 - mainly present in milk lipid vesicles - also binds to
DC-SIGN [25]. However, we measured DC-SIGN binding of the
aqueous phase of breast milk, which contains the BSSL
glycoprotein and excludes the lipids [15,25]. We therefore believe
that BSSL and not mucin 1 is the main source of the DC-SIGN
binding we measured.
DC-SIGN forms tetramers with four binding pockets that have
higher affinity for glycoproteins such as HIV gp120 than
monomeric DC-SIGN [26]. It therefore seems likely that
glycoproteins carrying multiple DC-SIGN interacting sugars will
have a higher affinity for DC-SIGN than glycoproteins with less of
such glycans. Since BSSL is polymorphic in the number of
potential O-glycosylation sites due to variation in the VNTR
domain this might translate into increased affinity of long BSSL
forms for DC-SIGN. In contrast, we initially found that breast
milks with small BSSL proteins have a stronger DC-SIGN binding
capacity than breast milk with large BSSL proteins. Our
genotyping studies showed that the LH genotype is associated
with stronger DC-SIGN binding than the LL and the HH
genotype. But the frequency of the LL genotype is low and gene
size variation may not always correlate with BSSL glycoprotein
size. The size of the processed glycoprotein may vary due to
differences in glycosylation among different individuals and also
truncated forms have been reported [27]. However, our
genotyping data may suggest that BSSL forms dimers and that
the combination of a low with a high repeat molecule provides the
combination with optimal DC-SIGN binding properties. This is
supported by the observation of McKillop and colleagues who
observed that purified BSSL protein forms dimers under native
conditions between either two equally or differently sized BSSL
proteins [28].
We speculate that not only the number of glycans could play a
role, but additionally other factors likely influence the DC-SIGN
binding properties of BSSL such as the three dimensional structure
of the protein. We propose that the quaternary structure of the
BSSL dimer complex plays an additional role in determining the
DC-SIGN binding properties by influencing the way BSSL sugars
are presented to DC-SIGN. The combination of a high and low
repeat BSSL protein is possibly presenting the best combination of
a high number of DC-SIGN interacting glycans with an optimal
three dimensional structure for binding to DC-SIGN.
Not all O-linked BSSL glycans carry DC-SIGN binding Lewis
sugars [23] and the number of Lewis sugars per BSSL molecule
may be influenced by variable activity of glycosidases [16,29]. The
activity of such enzymes may add an additional level of complexity
to the observed link between BSSL genotypes and DC-SIGN
Figure 2. DC-SIGN affinity of breast milk is highly variable
between mothers within cohorts and between different
cohorts. The DC-SIGN binding of milks from the Netherlands (NL),
Sweden (SW), Norway (NO) and Egypt (EG) is depicted as a percentage
of the highest overall binding sample (100%). Median DC-SIGN affinity is
indicated by a horizontal line for each cohort.
doi:10.1371/journal.pone.0017316.g002
BSSL Binding to DC-SIGN Varies with Genotype
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17316binding capacity of breast milk and enzyme expression levels may
vary over time during lactation as can the post-translational
glycosylation profiling which may also influence strength of
binding [30]. Specifically secretors, mothers that carry functional
fucosyltransferase 2 (FUT2) genes, may express different Lewis
type sugars than mothers deficient for FUT2 (non-secretors) [5].
Such differences as well as polymorphisms in other glycosylating
genes may well influence the number and type of DC-SIGN
binding glycans present on the BSSL glycoprotein. This extra
layer of complexity in glycoprotein expression may help explain
the different behavior of LL genotyped breast milks with regard to
DC-SIGN affinity in the Norwegian population versus Dutch
population. However, care should be taken because of the
relatively low number of LL genotyped mothers (n=9) in the
Dutch cohort and the high level of variation in DC-SIGN binding
observed in this group. Cloning and expression of recombinant
BSSL forms in cell lines should aid in further clarifying observed
differences in DC-SIGN binding between BSSL proteins with
variably sized repeat motifs.
Pathogen binding to DC-SIGN results in uptake by DCs and
subsequent antigen presentation to T-cells but this mechanism
appears to have been hijacked by some pathogens to promote their
transmission [7,31]. In addition to antigen presentation, pathogen
binding by DC-SIGN triggers signal transduction resulting in
modulation of DC immune activation status. DC-SIGN binding of
Lewis type or high mannose glycans results into two separate
routes of signaling depending on the glycan bound [32]. Human
milk, semen and cervicovaginal secretions contain factors that
interfere with the interaction between DC-SIGN and the
pathogen in vitro [14,33,34]. In vivo such secreted factors may
Figure 3. BSSL exon 11 is highly polymorphic in number of repeats. (a) Typical agarose gel analysis of BSSL exon 11 PCR genotyping
including 3 marker lanes and 7 genotyped DNA samples. (b) Allelic repeat number variation as determined by PCR analysis within each cohort.
Repeat number frequency is indicated as percentage of the total number of alleles within a cohort. (c) BSSL genotype distribution is highly variable in
all cohorts with most mothers having at least 1 allele with 16 repeats. Overview is plotted of the BSSL repeat number genotype combinations per
milk sample within each cohort.
doi:10.1371/journal.pone.0017316.g003
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to how HIV-1 or other pathogens may reach DCs in the sub-
epithelia We therefore suggest that the DC-SIGN blocking activity
of human secretions such as milk may partially help explain why
the risk of HIV-1 transmission via breastfeeding or sex is relatively
low. Furthermore, the interaction between breast milk and DC-
SIGN may influence the immune activation levels of DCs and
other immune cells during breastfeeding. We observed a high level
of variation in the DC-SIGN blocking properties of breast milk
from different mothers. For the infant this variation could result in
differential immune activation levels and differences in the risk of
infection, depending on the breastfeeding mother.
Although blocking the interaction between pathogen and DC-
SIGN may be beneficial against DC-SIGN mediated transmission,
receptor availability may still be necessary for inducing effective
adaptive immune responses against other pathogens. Such
conflicting roles for DC-SIGN may explain why the observed
variation in DC-SIGN binding properties of human milk may be
beneficial at the population level. Exposure to pathogens may result
in selective pressures in the direction of either strong or weak DC-
SIGN blocking depending on the type of circulating pathogens
dominating a specific population. We therefore speculate that the
observed geographical variation in DC-SIGN binding may be a
result of local selective pressures exerted over an evolutionary
timescale. However, care should be taken when interpreting the
observed geographical differences due to the relatively low numbers
of individuals in the Swedish and Egyptian samplings. We suggest
that variation in DC-SIGN blocking properties of mucosal
secretions might be a general theme in natural protection against
rapidly evolving mucosal pathogens. Therefore we speculate that
the identified BSSL size variation may represent one of multiple
strategies for a population to have variable levels of protection
against mucosal pathogens, as part of innate immunity.
Methods
Ethics statement
Medical ethical clearance was granted by the regional ethics
committee for medical research in Norway (for Norwegian
samples) and the ethics committee of the medical faculty of Umea
University (for Swedish samples) and with written informed
consent provided. Samples collected in the Netherlands and
Egypt were anonymous, single time-point collections of materials
to be discarded and therefore did not require medical ethical
clearance.
Processing of human milk
Human milk was collected from 269 breastfeeding mothers
from Sweden (n=21), Norway (n=146), The Netherlands (n=78)
and Egypt (n=24) and with no known timing with regards to the
age of the infants. The mothers were recruited from the general
population and do not necessarily represent mothers of the
countries from where the samples were taken. The milk was
centrifuged at 530 x g for 30 min at 4uC. The fat layer on top was
removed and the skim milk was collected to be used in DC-SIGN
binding experiments. The remaining cell pellet was resuspended in
L6 lysis buffer and the DNA was purified as previously described
[35].
SDS-PAGE and Western blot analysis
Processed human milk (skim milk) proteins were separated using
8% SDS-PAGE gels (Bio-Rad, Veenendaal, The Netherlands).
Gels were stained with Coomassie stain and the BSSL protein size
was estimated from gel. For immunoblotting the gels were blotted
on polyvinylidene difluoride membranes (PVDF-F; Millipore,
USA) and stained with DC-SIGN-Fc (R&D systems, Inc.,
England), and goat anti-human IgG1 antibody (Jackson Immu-
Figure 4. DC-SIGN binding capacity correlates to BSSL genotype. Alleles are defined as L (9 to 15 repeats) or H (16–19 repeats). The BSSL
genotype is plotted against DC-SIGN affinity for mothers from the Netherlands, Sweden, Norway and Egypt. LL, LH and HH genotypes are plotted
against DC-SIGN binding. Median DC-SIGN binding within cohorts is indicated by a horizontal line.
doi:10.1371/journal.pone.0017316.g004
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infrared imaging system (LI-COR Bioschiences, USA).
DC-SIGN binding ELISA
ELISA plates were coated with human milk 100 fold diluted in
0.2 M NaHCO3 buffer. Plates were blocked with 5% BSA and
subsequently incubated with a recombinant human DC-SIGN-Fc
chimera (R&D systems, Abingdon, England) in TSM buffer
(20 mM TRIS, 150 mM NaCl, 1 mM CaCl2 and 2 mM MgCl2)
containing 5% BSA as previously described [15,33]. Peroxidase
labeled anti human Ig-Fc antibodies (Jackson Immunology,
Baltimore, USA) were used to quantify the bound DC-SIGN-Fc.
Non specific binding of DC-SIGN-Fc was determined for each
individual sample by pre-incubating the calcium dependent DC-
SIGN-Fc for 20 min with 20 mM EGTA(Sigma-Aldrich, Zwijn-
drecht, The Netherlands).
Genotyping PCR
Lidberg and colleagues previously identified the carboxyl ester
lipase-like gene (CELL, genbank accession number M94580) with
high homology to the BSSL gene [36]. CELL contains a VNTR
domain resembling the exon 11 VNTR domain of BSSL although
Lidberg and colleagues reported the CELL VNTR to contain 7
repeats less than BSSL. Interference of CELL during the PCR
amplification of BSSL was prevented by designing primers that
indisputably only amplify BSSL exon 11 and not the CELL
VNTR. Primers (forward primer: ACCAACTTCCTGCGC-
TACTGGACCCTC, reverse primer: TGATACCAAGGCT-
CATGGGACGCTAAAAC) contained a FAM label for detection
(Eurogentec, Maastricht, The Netherlands). PCR was performed
with Reddy Mix PCR master mix (ABgene, Epsom, UK)
according to the suppliers’ standard protocol with betain (Sigma,
St Louis, USA) added to a final concentration of 1.5 M. After
initial denaturation for 49 at 94uC the following program was run
for 35 cycles: 300 94uC, 39 60uC, 19 72uC followed by an extended
elongation for 79 at 72uC. The PCR product was mixed with the
Genescan
TM –1200 LIZH Standard (Applied Biosystems, Foster
city, USA) and the ABI 3100 capillary sequencer (Applied
Biosystems, Foster city, USA) in Genescan mode was used for
PCR product size determination. Genemapper software (Applied
Biosystems, Foster city, USA) was used to analyze the data.
Statistical analysis
BSSL protein sizes are presented as individual observations.
Average values of triplicate DC-SIGN binding capacity measure-
ments were plotted. Median values are indicated in the figures. A
Mann-Whitney test was used to compare BSSL protein size of the
weak and strong DC-SIGN binding capacity groups. The Kruskal-
Wallis test, with subsequent pairwise Mann-Whitney tests in case
of an overall significant difference was used to analyze differences
in DC-SIGN binding capacity between cohorts. Fisher-Exact test
was used to compare allele frequencies between the cohorts. A
non-parametric ANOVA (rank transformed values), with adjust-
ment for cohort and the cohort*genotype interaction was used to
analyze the effect of the genotype on DC-SIGN binding capacity.
SPSS (release 17, SPSS Inc., USA) was used for all analyses and
p-values ,0.05 were considered statistically significant.
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